Quick Answer
Matinas BioPharma Holdings, Inc. reported Total Revenue of $1.10 million for fiscal year 2023.
Matinas BioPharma Holdings, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2023 | $1.10M | -65.6% |
| 2022 | $3.19M | +9560.6% |
| 2021 | $33.0K | -79.2% |
| 2020 | $158.3K | +76.3% |
| 2019 | $89.8K | -25.0% |
| 2018 | $119.8K | -20.0% |
| 2017 | $149.7K | — |
| 2016 | $0.00 | -100.0% |
| 2015 | $194.5K | — |
| 2014 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $1.10M | — | +3.1% |
| September 30, 2022 | $1.06M | — | +0.0% |
| June 30, 2022 | $1.06M | — | +3089.0% |
| March 31, 2021 | $33.3K | — | -65.2% |
| September 30, 2020 | $95.8K | — | +6.7% |
| June 30, 2019 | $89.8K | -0.0% | -0.0% |
| June 30, 2018 | $89.8K | +100.0% | +200.0% |
| March 31, 2018 | $29.9K | +100.0% | -33.3% |
- Matinas BioPharma Holdings, Inc. showed a decrease of -65.6% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from Matinas BioPharma Holdings, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: